Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA† (Englisch)
- Neue Suche nach: Krop, I. E.
- Neue Suche nach: Lin, N. U.
- Neue Suche nach: Blackwell, K.
- Neue Suche nach: Guardino, E.
- Neue Suche nach: Huober, J.
- Neue Suche nach: Lu, M.
- Neue Suche nach: Miles, D.
- Neue Suche nach: Samant, M.
- Neue Suche nach: Welslau, M.
- Neue Suche nach: Diéras, V.
- Neue Suche nach: Krop, I. E.
- Neue Suche nach: Lin, N. U.
- Neue Suche nach: Blackwell, K.
- Neue Suche nach: Guardino, E.
- Neue Suche nach: Huober, J.
- Neue Suche nach: Lu, M.
- Neue Suche nach: Miles, D.
- Neue Suche nach: Samant, M.
- Neue Suche nach: Welslau, M.
- Neue Suche nach: Diéras, V.
In:
ANNALS OF ONCOLOGY
;
26
, 1
;
113-119
;
2015
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†
-
Beteiligte:Krop, I. E. ( Autor:in ) / Lin, N. U. ( Autor:in ) / Blackwell, K. ( Autor:in ) / Guardino, E. ( Autor:in ) / Huober, J. ( Autor:in ) / Lu, M. ( Autor:in ) / Miles, D. ( Autor:in ) / Samant, M. ( Autor:in ) / Welslau, M. ( Autor:in ) / Diéras, V. ( Autor:in )
-
Erschienen in:ANNALS OF ONCOLOGY ; 26, 1 ; 113-119
-
Verlag:
- Neue Suche nach: OXFORD UNIVERSITY PRESS
-
Erscheinungsdatum:01.01.2015
-
Format / Umfang:7 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.992
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.992 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 26, Ausgabe 1
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1
-
thanks to referees 2014| 2015
- 7
-
Phase I trials in oncology: a new era has startedPostel-Vinay, S. / Soria, J. C. et al. | 2015
- 9
-
Challenges in combining novel molecularly targeted agents in cancer medicineYap, T. A. et al. | 2015
- 11
-
Pushing the boundaries of somatic copy-number variation detection: advances and challengesSathirapongsasuti, J. F. et al. | 2015
- 13
-
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsSorich, M. J. / Wiese, M. D. / Rowland, A. / Kichenadasse, G. / McKinnon, R. A. / Karapetis, C. S. et al. | 2015
- 21
-
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)†Maschmeyer, G. / Carratalà, J. / Buchheidt, D. / Hamprecht, A. / Heussel, C. P. / Kahl, C. / Lorenz, J. / Neumann, S. / Rieger, C. / Ruhnke, M. et al. | 2015
- 33
-
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevanceKhoja, L. / Lorigan, P. / Dive, C. / Keilholz, U. / Fusi, A. et al. | 2015
- 40
-
Immune biomarkers of anti-EGFR monoclonal antibody therapyTrivedi, S. / Concha-Benavente, F. / Srivastava, R. M. / Jie, H. B. / Gibson, S. P. / Schmitt, N. C. / Ferris, R. L. et al. | 2015
- 47
-
Estimates of benefits and harms of prophylactic use of aspirin in the general populationCuzick, J. / Thorat, M. A. / Bosetti, C. / Brown, P. H. / Burn, J. / Cook, N. R. / Ford, L. G. / Jacobs, E. J. / Jankowski, J. A. / La Vecchia, C. et al. | 2015
- 58
-
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsTolcher, A. W. / Bendell, J. C. / Papadopoulos, K. P. / Burris, H. A. / Patnaik, A. / Jones, S. F. / Rasco, D. / Cox, D. S. / Durante, M. / Bellew, K. M. et al. | 2015
- 64
-
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataFavero, F. / Joshi, T. / Marquard, A. M. / Birkbak, N. J. / Krzystanek, M. / Li, Q. / Szallasi, Z. / Eklund, A. C. et al. | 2015
- 70
-
Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDERSun, Z. / Prat, A. / Cheang, M. C. / Gelber, R. D. / Perou, C. M. et al. | 2015
- 75
-
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapySheri, A. / Smith, I. E. / Johnston, S. R. / A'Hern, R. / Nerurkar, A. / Jones, R. L. / Hills, M. / Detre, S. / Pinder, S. E. / Symmans, W. F. et al. | 2015
- 81
-
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survivalTobin, N. P. / Harrell, J. C. / Lövrot, J. / Egyhazi Brage, S. / Frostvik Stolt, M. / Carlsson, L. / Einbeigi, Z. / Linderholm, B. / Loman, N. / Malmberg, M. et al. | 2015
- 89
-
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancerCao, K. I. / Lebas, N. / Gerber, S. / Levy, C. / Le Scodan, R. / Bourgier, C. / Pierga, J. Y. / Gobillion, A. / Savignoni, A. / Kirova, Y. M. et al. | 2015
- 95
-
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy†Lindner, J. L. / Loibl, S. / Denkert, C. / Ataseven, B. / Fasching, P. A. / Pfitzner, B. M. / Gerber, B. / Gade, S. / Darb-Esfahani, S. / Sinn, B. V. et al. | 2015
- 101
-
Obesity and the outcome of young breast cancer patients in the UK: the POSH studyCopson, E. R. / Cutress, R. I. / Maishman, T. / Eccles, B. K. / Gerty, S. / Stanton, L. / Altman, D. G. / Durcan, L. / Wong, C. / Simmonds, P. D. et al. | 2015
- 113
-
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†Krop, I. E. / Lin, N. U. / Blackwell, K. / Guardino, E. / Huober, J. / Lu, M. / Miles, D. / Samant, M. / Welslau, M. / Diéras, V. et al. | 2015
- 120
-
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancerTreilleux, I. / Arnedos, M. / Cropet, C. / Wang, Q. / Ferrero, J. M. / Abadie-Lacourtoisie, S. / Levy, C. / Legouffe, E. / Lortholary, A. / Pujade-Lauraine, E. et al. | 2015
- 126
-
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial†Klingbiel, D. / Saridaki, Z. / Roth, A. D. / Bosman, F. T. / Delorenzi, M. / Tejpar, S. et al. | 2015
- 132
-
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trialÉlez, E. / Kocáková, I. / Höhler, T. / Martens, U. M. / Bokemeyer, C. / Van Cutsem, E. / Melichar, B. / Smakal, M. / Csőszi, T. / Topuzov, E. et al. | 2015
- 141
-
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerYamada, Y. / Higuchi, K. / Nishikawa, K. / Gotoh, M. / Fuse, N. / Sugimoto, N. / Nishina, T. / Amagai, K. / Chin, K. / Niwa, Y. et al. | 2015
- 149
-
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyVan Cutsem, E. / Boni, C. / Tabernero, J. / Massuti, B. / Middleton, G. / Dane, F. / Reichardt, P. / Pimentel, F. L. / Cohn, A. / Follana, P. et al. | 2015
- 156
-
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growthKobayashi, Y. / Mitsudomi, T. / Sakao, Y. / Yatabe, Y. et al. | 2015
- 161
-
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencingSun, J. M. / Choi, Y. L. / Ji, J. H. / Ahn, J. S. / Kim, K. M. / Han, J. / Ahn, M. J. / Park, K. et al. | 2015
- 167
-
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study†Necchi, A. / Mariani, L. / Di Nicola, M. / Lo Vullo, S. / Nicolai, N. / Giannatempo, P. / Raggi, D. / Farè, E. / Magni, M. / Piva, L. et al. | 2015
- 173
-
Renal impairment and late toxicity in germ-cell cancer survivorsLauritsen, J. / Mortensen, M. S. / Kier, M. G. / Christensen, I. J. / Agerbaek, M. / Gupta, R. / Daugaard, G. et al. | 2015
- 179
-
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trialCella, D. / Ivanescu, C. / Holmstrom, S. / Bui, C. N. / Spalding, J. / Fizazi, K. et al. | 2015
- 185
-
Differences among young adults, adults and elderly chronic myeloid leukemia patientsCastagnetti, F. / Gugliotta, G. / Baccarani, M. / Breccia, M. / Specchia, G. / Levato, L. / Abruzzese, E. / Rossi, G. / Iurlo, A. / Martino, B. et al. | 2015
- 193
-
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomasBouabdallah, K. / Furst, S. / Asselineau, J. / Chevalier, P. / Tournilhac, O. / Ceballos, P. / Vigouroux, S. / Tabrizi, R. / Doussau, A. / Bouabdallah, R. et al. | 2015
- 198
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decadesDas, L. C. / Karrison, T. G. / Witt, M. E. / Muller, C. / Stenson, K. / Blair, E. A. / Cohen, E. E. / Seiwert, T. Y. / Haraf, D. J. / Vokes, E. E. et al. | 2015
- 205
-
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinomaChen, Y. P. / Wang, Z. X. / Chen, L. / Liu, X. / Tang, L. L. / Mao, Y. P. / Li, W. F. / Lin, A. H. / Sun, Y. / Ma, J. et al. | 2015
- 211
-
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agencyMaeda, H. / Kurokawa, T. et al. | 2015
- 217
-
Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?Gioulbasanis, I. / Martin, L. / Baracos, V. E. / Thézénas, S. / Koinis, F. / Senesse, P. et al. | 2015
- 221
-
Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†Wang, A. / Kubo, J. / Luo, J. / Desai, M. / Hedlin, H. / Henderson, M. / Chlebowski, R. / Tindle, H. / Chen, C. / Gomez, S. et al. | 2015
- 231
-
Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapyBylicki, O. / Gan, H. K. / Joly, F. / Maillet, D. / You, B. / Péron, J. et al. | 2015
- 238
-
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategiesIlie, M. I. / Bence, C. / Hofman, V. / Long-Mira, E. / Butori, C. / Bouhlel, L. / Lalvée, S. / Mouroux, J. / Poudenx, M. / Otto, J. et al. | 2015
- 245
-
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?Abali, H. / Yavuz, S. / Calıkusu, Z. / Seyrek, E. et al. | 2015
- 245
-
Reply to the Letter to the Editor ‘Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?’ by Abali et al.Sugihara, K. / Yoshida, M. / Ishiguro, M. et al. | 2015
- 246
-
A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenibRechsteiner, M. / Wild, P. / Kiessling, M. K. / Bohnert, A. / Zhong, Q. / Stahel, R. A. / Moch, H. / Curioni-Fontecedro, A. et al. | 2015
- 248
-
Pharmacokinetic interaction involving fenofibrate and everolimusMir, O. / Poinsignon, V. / Arnedos, M. / Delaloge, S. / Paci, A. et al. | 2015
- 249
-
Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al.Bertelli, G. / Quinton, A. E. / Lewis, P. D. / Ali, P. / Morgan, C. et al. | 2015
- 250
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.Schilling, B. / Sondermann, W. / Griewank, K. G. / Livingstone, E. / Zimmer, L. / Hillen, U. / Schadendorf, D. et al. | 2015
- 251
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Schilling et al.Davar, D. / Choi, T. / Kirkwood, J. M. et al. | 2015
- 252
-
Letter to the editor concerning ‘Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies’Hassan, W. A. / Bjerre, M. / Hjortebjerg, R. / Magnusson, N. E. / Ramshanker, N. / Frystyk, J. et al. | 2015
- 254
-
P–0271 Concurrent oral UFT and pelvic irradiation as neoadjuvant chemoradiation for operable rectal cancer: a phase II studyHelmy, S. / Abo-Zeid, A. A. / Gado, N. M. / Salman, M. I. / Bassyoni, M. M. / Abd Al Samee, A. / Salem, D. A. et al. | 2015